



www.bioinformation.net
Volume 22(8)



Research Article

Received August 1, 2026; Revised August 31, 2026; Accepted August 31, 2026, Published August 31, 2026

DOI: 10.6026/973206300225497

SJIF 2026 (Scientific Journal Impact Factor for 2026) = 8.478

2022 Impact Factor (2023 Clarivate Inc. release) is 1.9

Declaration on Publication Ethics:

The author's state that they adhere with COPE guidelines on publishing ethics as described elsewhere at <https://publicationethics.org/>. The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any information that is misleading to the publisher in regard to this article.

Declaration on official E-mail:

The corresponding author declares that lifetime official e-mail from their institution is not available for all authors

License statement:

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License

Comments from readers:

Articles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to the original article without open access charges. Comments should be concise, coherent and critical in less than 1000 words.

Disclaimer:

Bioinformation provides a platform for scholarly communication of data and information to create knowledge in the Biological/Biomedical domain after adequate peer/editorial reviews and editing entertaining revisions where required. The views and opinions expressed are those of the author(s) and do not reflect the views or opinions of Bioinformation and (or) its publisher Biomedical Informatics. Biomedical Informatics remains neutral and allows authors to specify their address and affiliation details including territory where required.

Edited by Hiroj Bagde
E-mail: hirojbagde8@gmail.com
Phone: +91 9766105900

Citation: Boyapati *et al.* Bioinformation 22(8): 5497-5501 (2026)

Association between periodontal inflammation and cognitive impairment among older adults: A clinical and biomarker-based study

Ramanarayana Boyapati^{1,*}, Krishna Rao Kilaru², Sai Archita Tummala³, Bhavyasri Gaddam⁴, Lalitha Chintala⁵ & Ravindranath Dhulipalla⁶

¹Department of Periodontology, Sibar Institute of Dental Sciences, Takkellapadu, Guntur, Andhra Pradesh, India; ²Department of Dentistry, School of Dental Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America; ³Department of Dentistry, EHR and Claims Analytics, Flair Dental, McKinney, Texas 75070, United States of America; ⁴Department of Oral Diagnostic Sciences & Research, School of Dentistry, Meharry Medical College, Nashville, Tennessee 37208, United States of America; ⁵Department of Oral Medicine and Radiology, Malla Reddy Institute of Dental Sciences, Malla Reddy Vishwavidyapeet (Deemed to

be University), Suraram, Hyderabad, Telangana, India; ⁶Department of Periodontology, Sibar Institute of Dental Sciences, Takkellapadu, Guntur andhra Pradesh, India; *Corresponding author

Affiliation URL:

<https://sids.ac.in/>
<https://www.pitt.edu/>
<https://flair-dental.com/>
<https://meharry.edu/>
<https://mrvv.edu.in/>
<https://sids.ac.in/>

Author contact:

Ramanarayana Boyapati - E-mail: dr.ramanarayana@gmail.com
 Krishna Rao Kilaru - E-mail: kk167@pitt.edu
 Sai Archita Tummala - E-mail: drarchitatummala3@gmail.com
 Bhavyasri Gaddam - E-mail: Bgadd335@mmc.edu
 Lalitha Chintala - E-mail: lalitha.chintala@mrvv.edu.in
 Ravindranath Dhulipalla - E-mail: ravident69@gmail.com

Abstract:

Cognitive impairment in older adults is influenced by chronic inflammatory exposures and periodontal inflammation may represent a modifiable contributor to systemic inflammatory burden. This clinical and biomarker-based cross-sectional study evaluated 180 adults aged 60 years and older using periodontal examination, periodontal inflamed surface area, Mini-Mental State Examination, Montreal Cognitive Assessment and serum inflammatory markers. Mild cognitive impairment was identified in 68 participants (37.8%) and these participants had significantly higher periodontal inflamed surface area ($864 \pm 318 \text{ mm}^2$) than cognitively normal participants ($523 \pm 246 \text{ mm}^2$; $p < 0.001$). Periodontal inflamed surface area correlated inversely with MoCA score ($r = -0.43$, $p < 0.001$) and remained independently associated with mild cognitive impairment after adjustment for age, education, diabetes, hypertension and serum C-reactive protein (adjusted OR=1.82 per 250 mm^2 , $p = 0.006$). Thus, periodontal inflammatory burden was associated with poor cognitive performance and high systemic inflammation, supporting integrated oral and geriatric health assessment.

Keywords: Periodontitis, cognitive impairment, older adults, MoCA, MMSE, PISA, inflammatory biomarkers

Background:

Cognitive impairment is a growing public health challenge in aging populations. Mild cognitive impairment may precede dementia and is influenced by vascular, metabolic, neurodegenerative, inflammatory and lifestyle-related factors [1-4]. Periodontitis is a chronic inflammatory disease that increases with age and can remain active for years if untreated. The inflamed periodontal pocket provides a biological interface for microbial products, inflammatory mediators and systemic immune activation [5-8]. A growing body of evidence suggests an association between poor periodontal health and cognitive impairment. Proposed mechanisms include systemic inflammation, endothelial dysfunction, microbial translocation, immune priming and direct or indirect neuroinflammatory pathways [9-12]. Oral pathogens and their virulence factors have been investigated in relation to neurodegenerative processes. Although causality remains unproven, periodontal infection may contribute to inflammatory cascades that are relevant to cognitive decline, especially in vulnerable older adults [13-16]. Serum C-reactive protein, interleukin-6 and tumor necrosis factor-alpha are markers of systemic inflammation that have been associated with both periodontitis and cognitive impairment. These biomarkers may help clarify whether periodontal burden relates to cognition through inflammatory

pathways [17-20]. Clinical periodontal indices such as probing pocket depth and clinical attachment level describe disease severity, but they do not fully express the current inflammatory surface area. The periodontal inflamed surface area quantifies bleeding pocket epithelium and may better represent active inflammatory burden [21-23]. Cognitive screening tools such as the Mini-Mental State Examination and Montreal Cognitive Assessment are widely used in older adults. The Montreal Cognitive Assessment is particularly sensitive for mild cognitive impairment because it captures executive function, attention and visuospatial domains [24-27]. Previous studies have often relied on tooth loss or self-reported periodontal status, which may underrepresent active inflammation. Studies combining clinical periodontal examination, cognitive testing and serum biomarkers may provide stronger evidence [28-30]. Therefore, it is of interest to evaluate the association between periodontal inflammatory burden, cognitive performance and systemic inflammatory biomarkers in older adults.

Materials and Methods:

This cross-sectional clinical and biomarker-based study included 180 community-dwelling adults aged 60 years and older attending dental and geriatric outpatient clinics. Participants were recruited consecutively over 10 months after obtaining

informed consent. Inclusion criteria were age ≥ 60 years, ability to undergo oral examination and presence of at least 10 natural teeth. Exclusion criteria were diagnosed dementia, Parkinson disease, stroke within 6 months, severe depression, severe hearing or visual impairment preventing cognitive testing, current infection, antibiotic use within 3 months, periodontal treatment within 6 months, malignancy, immunosuppressive therapy and inability to provide reliable history. Demographic data included age, sex, education, socioeconomic status, medical history, medication use, diabetes, hypertension, body mass index, tobacco status and tooth brushing frequency. Cognitive assessment was performed using the Mini-Mental State Examination and Montreal Cognitive Assessment by a trained examiner blinded to periodontal status. Mild cognitive impairment was defined using education-adjusted MoCA thresholds with preserved basic activities of daily living. Full-mouth periodontal examination included plaque index, bleeding on probing, probing pocket depth, clinical attachment level, number of remaining teeth and periodontal inflamed surface area. Six sites per tooth were examined using a calibrated periodontal probe. Serum high-sensitivity C-reactive protein, interleukin-6 and tumor necrosis factor- α were measured using standardized laboratory assays. Data were analyzed using SPSS version 26. Participants were categorized as cognitively normal or mild cognitive impairment. Intergroup comparisons used independent t-test, Mann-Whitney U test, or chi-square test. Correlations between periodontal and cognitive variables were assessed using Pearson or Spearman correlation. Logistic regression evaluated independent association between periodontal inflamed surface area and mild cognitive impairment after adjustment for covariates. A p-value <0.05 was considered significant.

Results:

The study included 180 older adults with mean age of 67.8 ± 6.1 years; 94 (52.2%) were female. Mild cognitive impairment was identified in 68 participants (37.8%). Participants with mild cognitive impairment were older, had fewer years of education and had a higher frequency of diabetes and hypertension than cognitively normal participants. Periodontal inflammation was significantly higher in the mild cognitive impairment group. Mean periodontal inflamed surface area was 864 ± 318 mm² in participants with mild cognitive impairment and 523 ± 246 mm² in cognitively normal participants ($p<0.001$). Mean probing pocket depth, clinical attachment level, bleeding on probing and number of sites with pocket depth ≥ 5 mm were also significantly higher in the mild cognitive impairment group. Serum high-sensitivity C-reactive protein, interleukin-6 and tumor necrosis factor- α were higher in participants with mild cognitive impairment. Periodontal inflamed surface area correlated inversely with MoCA score ($r=-0.43$, $p<0.001$) and MMSE score ($r=-0.31$, $p<0.001$). In multivariable logistic regression, periodontal inflamed surface area remained independently associated with mild cognitive impairment after adjustment for age, sex, education, diabetes, hypertension, body mass index, smoking and serum inflammatory markers.

Table 1: Demographic and medical characteristics by cognitive status

Variable	Cognitively normal (n=112)	MCI (n=68)	p value
Age (years)	66.1 $\pm$ 5.4	70.6 $\pm$ 6.2	<0.001
Female sex, n (%)	57 (50.9%)	37 (54.4%)	0.646
Education (years)	10.8 $\pm$ 3.9	8.6 $\pm$ 3.7	<0.001
Diabetes, n (%)	31 (27.7%)	30 (44.1%)	0.023
Hypertension, n (%)	48 (42.9%)	42 (61.8%)	0.014
Current/former tobacco use	24 (21.4%)	19 (27.9%)	0.318
Remaining teeth	22.6 $\pm$ 5.1	19.4 $\pm$ 5.8	<0.001

Table 2: Periodontal and inflammatory biomarker comparison

Parameter	Cognitively normal	MCI	p value
Plaque index	1.72 $\pm$ 0.48	2.06 $\pm$ 0.52	<0.001
Bleeding on probing (%)	31.8 $\pm$ 14.7	48.6 $\pm$ 16.2	<0.001
Mean PPD (mm)	3.28 $\pm$ 0.62	4.05 $\pm$ 0.74	<0.001
Mean CAL (mm)	3.82 $\pm$ 0.89	4.71 $\pm$ 1.02	<0.001
PISA (mm ²)	523 $\pm$ 246	864 $\pm$ 318	<0.001
hs-CRP (mg/L)	2.8 $\pm$ 1.3	4.1 $\pm$ 1.8	<0.001
IL-6 (pg/mL)	3.9 $\pm$ 1.5	5.4 $\pm$ 2.1	<0.001
TNF- α (pg/mL)	9.8 $\pm$ 3.6	12.3 $\pm$ 4.2	<0.001

Table 3: Correlation and logistic regression analysis

Analysis	Variable	Estimate	95% CI	p value
Correlation	PISA vs MoCA	$r=-0.43$	--	<0.001
Correlation	PISA vs MMSE	$r=-0.31$	--	<0.001
Correlation	IL-6 vs MoCA	$r=-0.36$	--	<0.001
Regression	PISA per 250 mm ²	OR=1.82	1.19 to 2.78	0.006
Regression	Mean CAL per 1 mm	OR=1.41	1.01 to 1.96	0.041
Regression	hs-CRP per 1 mg/L	OR=1.22	1.03 to 1.45	0.022

Discussion:

The present study found that older adults with mild cognitive impairment had significantly greater periodontal inflammatory burden than cognitively normal participants. The association remained significant after adjustment for demographic, vascular, metabolic and inflammatory covariates, suggesting that periodontal inflammation may be independently linked with poorer cognitive performance [31, 32]. The periodontal inflamed surface area showed a stronger relationship with MoCA score than conventional mean probing depth or attachment level. This supports the idea that active inflammatory burden, rather than cumulative tissue destruction alone, may be more relevant to systemic inflammatory exposure [33, 34]. Higher serum C-reactive protein, interleukin-6 and tumor necrosis factor- α in the mild cognitive impairment group indicate a systemic inflammatory phenotype. Periodontal inflammation may contribute to this phenotype, although systemic inflammation is multifactorial and may also arise from adiposity, diabetes, vascular disease and aging [35]. The biological pathways linking periodontal inflammation and cognition may include circulating cytokines, blood-brain barrier alteration, microglial activation, endothelial dysfunction and exposure to periodontal microbial products. These mechanisms are plausible, but the present cross-sectional design cannot prove directionality [1-4]. Tooth loss was more common among participants with mild cognitive impairment, but the study focused on active periodontal inflammation among dentate individuals. Tooth loss may reflect previous periodontal disease, socioeconomic factors, nutrition and access to care; therefore, it should not be interpreted as a direct substitute for current inflammation [5-8]. The use of both MMSE and MoCA was important because MoCA is more

sensitive for mild cognitive deficits. The stronger association with MoCA suggests that periodontal inflammatory burden may relate to early or subtle cognitive changes rather than only advanced impairment [24-27]. Clinical implications include the need for oral health assessment in older adults at risk of cognitive decline. Periodontal therapy, plaque control, caregiver involvement and maintenance care may reduce oral inflammatory burden. Whether this can slow cognitive decline requires interventional trials [9-12]. The limitations include cross-sectional design, single-center recruitment, possible residual confounding and use of screening rather than comprehensive neuropsychological testing. Longitudinal studies should evaluate whether periodontal treatment reduces systemic inflammatory biomarkers and preserves cognitive trajectories in older adults [13-20]. Recent studies likewise report that severe periodontal inflammation is associated with poorer cognitive performance in older adults, including biomarker-based case-control and community studies; however, these observational findings do not establish causality [7, 36 and 37]. The association observed in this study is clinically important because periodontal inflammation is potentially modifiable. Older adults with cognitive decline often experience worsening oral hygiene because of reduced dexterity, memory impairment, medication-related xerostomia and dependence on caregivers. This creates a cycle in which cognitive impairment worsens periodontal status, while periodontal inflammation may contribute to systemic inflammatory burden. Caregiver involvement is therefore essential. Oral hygiene instructions directed only to the patient may be insufficient when mild cognitive impairment is present. Dental professionals should assess whether the patient can perform brushing and interdental cleaning independently and should involve family members or caregivers in maintenance planning. Recall intervals may need to be shortened for patients with both periodontal inflammation and cognitive vulnerability. The use of periodontal inflamed surface area adds value because it captures active bleeding pocket epithelium. In older adults, clinical attachment loss may reflect historical disease and tooth retention patterns, whereas bleeding pocket area more closely reflects current inflammatory exposure. This may explain why periodontal inflamed surface area remained independently associated with cognitive impairment after adjustment. The study also suggests that oral health should be included in geriatric risk assessment. Cognitive screening clinics frequently assess vascular risk factors, diabetes, nutrition, medication burden and depression, but periodontal status is often overlooked. Integrating dental referral into geriatric pathways could improve quality of life and may reduce one contributor to chronic inflammation. Future longitudinal studies should evaluate whether periodontal treatment changes cognitive trajectories or only improves inflammatory biomarkers. Randomized trials in older adults will require careful ethical design, caregiver support, standardized periodontal maintenance and repeated cognitive testing. Such research can clarify whether periodontal therapy is a preventive strategy, a supportive care measure, or both. Reverse causation remains a key concern. Individuals with early cognitive impairment may

neglect oral hygiene, miss dental appointments and develop more periodontal inflammation. At the same time, periodontal inflammation may amplify systemic inflammatory pathways that influence brain health. The relationship is therefore likely bidirectional and longitudinal designs are required to separate cause, consequence and shared risk factors. Nutritional pathways may also contribute. Periodontitis and tooth loss can impair chewing efficiency, leading to avoidance of fibrous foods, fruits, vegetables and protein-rich items. Poor diet may worsen metabolic and inflammatory profiles, which in turn can affect cognitive resilience. Future studies should include dietary assessment, masticatory function and socioeconomic variables to clarify these indirect pathways. Another clinical implication is medication review. Older adults commonly use antihypertensives, antidepressants, anticholinergics and other medications that can reduce salivary flow and increase plaque accumulation. Xerostomia may worsen periodontal inflammation and caries risk. Integrated assessment of medications, saliva, cognition and periodontal status may improve prevention strategies in geriatric dentistry. The findings should not be used to suggest that periodontal disease alone causes cognitive impairment. Cognitive decline is multifactorial and influenced by age, education, vascular disease, genetics, depression, sleep and social engagement. Periodontal inflammation should be viewed as one potentially modifiable component within a broader risk profile.

Conclusion:

Older adults with mild cognitive impairment showed greater periodontal inflammatory burden and higher serum inflammatory biomarkers than cognitively normal participants. Periodontal inflamed surface area was independently associated with mild cognitive impairment and inversely correlated with MoCA and MMSE scores. These findings support the integration of periodontal evaluation into geriatric health assessment and justify longitudinal trials examining whether periodontal inflammation control influences cognitive outcomes.

References:

- [1] Noble JM *et al.* *J Neurol Neurosurg Psychiatry*. 2009 **80**:1206. [PMID: 19419981].
- [2] Chen CK *et al.* *Alzheimers Res Ther*. 2017 **9**:56. [PMID: 28784164].
- [3] Sochocka M *et al.* *Curr Neuroparmacol*. 2017 **15**:996. [PMID: 28294067].
- [4] Nascimento PC *et al.* *Front Neurol*. 2019 **10**:323. [PMID: 31105630].
- [5] Li A *et al.* *J Periodontol*. 2022 **93**:1302. [PMID: 35363382].
- [6] Fu YD *et al.* *BMC Oral Health*. 2024 **24**:1131. [PMID: 39350376].
- [7] Brahmbhatt Y *et al.* *Life (Basel)*. 2024 **14**:1589. [PMID: 39768299].
- [8] Carballo A *et al.* *J Clin Periodontol*. 2023 **50**:1444. [PMID: 37584311].
- [9] Saji N *et al.* *BMC Oral Health*. 2025 **25**:373. [PMID: 40082811].

- [10] Ochnik M *et al.* *Int J Mol Sci.* 2025 **26**:11752. [PMID: 41373897].
- [11] Ramadhani A *et al.* *Dent J (Basel).* 2025 **13**:505. [PMID: 41294487].
- [12] Hu X *et al.* *Psychogeriatrics.* 2021 **21**:813. [PMID: 34247432].
- [13] Laugisch O *et al.* *J Alzheimers Dis.* 2018 **66**:105. [PMID: 30223397].
- [14] Leira Y *et al.* *Neuroepidemiology.* 2017 **48**:21. [PMID: 28219071].
- [15] Ide M *et al.* *PLoS One.* 2016 **11**:e0151081. [PMID: 26963387].
- [16] Kamer AR *et al.* *J Alzheimers Dis.* 2012 **28**:613. [PMID: 22045483].
- [17] Kamer AR *et al.* *Periodontol 2000.* 2020 **83**:242. [PMID: 32385876].
- [18] Karaduran K *et al.* *Clin Oral Investig.* 2024 **28**:67. [PMID: 38159159].
- [19] Poole S *et al.* *Alzheimers Dis.* 2013 **36**:665. [PMID: 23666172].
- [20] Dominy SS *et al.* *Sci Adv.* 2019 **5**:eaau3333. [PMID: 30746447].
- [21] Hajishengallis G. *Nat Rev Immunol.* 2015 **15**:30b. [PMID: 25534621].
- [22] Holmes C & Butchart J. *Biochem Soc Trans.* 2011 **39**:898. [PMID: 21787320].
- [23] Heneka MT *et al.* *Lancet Neurol.* 2015 **14**:388. [PMID: 25792098].
- [24] Cunningham C. *Biochem Soc Trans.* 2011 **39**:945. [PMID: 21787328].
- [25] Dimayuga FO *et al.* *J Neuroimmunol.* 2005 **161**:123. [PMID: 15748951].
- [26] Nasreddine ZS *et al.* *J Am Geriatr Soc.* 2005 **53**:695. [PMID: 15817019].
- [27] Folstein MF *et al.* *J Psychiatr Res.* 1975 **12**:189 [PMID: 1202204].
- [28] Petersen RC *et al.* *J Intern Med.* 2004 **256**:183 [PMID: 15324362].
- [29] Albert MS *et al.* *Alzheimers Dement.* 2011 **7**:270. [PMID: 21514249].
- [30] Jack CR *et al.* *Alzheimers Dement.* 2018 **14**:535. [PMID: 29653606].
- [31] Papapanou PN *et al.* *J Periodontol.* 2018 **89**:S173. [PMID: 29926951].
- [32] Tonetti MS *et al.* *J Periodontol.* 2018 **89**:S159. [PMID: 29926952].
- [33] Nesse W *et al.* *J Clin Periodontol.* 2008 **35**:668. [PMID: 18564145].
- [34] Pazos P *et al.* *Neurologia.* 2018 **33**:602. [PMID: 27780615].
- [35] Karaduran K *et al.* *Curr Alzheimer Res.* 2025 **22**:302. [PMID: 40396318].
- [36] Buhlin K *et al.* *J Periodontol.* 2026 **97**:919. [PMID: 41211647].
- [37] Igase M *et al.* *JAR Life.* 2024 **13**:108. [PMID: 39649137].

Caveat Emptor is applicable among the literate community where required and possible. The publisher, its journal, editors and the internal/external reviewers take adequate steps to check, evaluate, correct, edit, revise and improve content where possible and required.